Abstract
Objectives: To investigate the anatomical distribution, morphological abnormalities and response to adalimumab therapy of ultrasound(US)-detected peripheral enthesitis in patients with axial spondyloarthritis (SpA).Methods: In a randomized, placebo-controlled, double-blinded, investigator-initiated trial (NCT01029847), patients with axial SpA according to the Assessment of Spondyloarthritis International Society criteria were randomized to subcutaneous adalimumab 40 mg every other week or placebo from baseline to week 6. From week 6 to 24, all patients received adalimumab 40 mg every other week. Of 49 patients enrolled, 21 patients participated in our observational US sub-study. US assessment applying the OMERACT US definitions for enthesitis of 10 peripheral entheseal regions of the upper and lower extremities and clinical examination were performed at baseline, weeks 6 and 24. US was performed by one experienced investigator. Hypo-echogenicity, increased thickness and Doppler activity of the enthesis were considered signs of active inflammation, whereas insertional bone erosions, intratendinous calcifications, and enthesophytes were regarded as signs of structural lesions.Results: Enthesitis on US was mostly present in the lower limbs, especially in the Achilles tendon (81%), the quadriceps tendon (62%), and the greater femoral trochanter (52%). Structural lesions were predominant (38 vs. 12% of examined entheses with inflammatory changes), particularly in the entheses of the lower limbs, and exhibited no change during treatment.Conclusion: US-detected structural lesions were common while inflammatory lesions were relatively rare in patients initiating adalimumab due to axial SpA. Structural lesions did not appear to change during 24 weeks follow-up, suggesting that these lesions may not be helpful outcome measures in short-term clinical trials.
Highlights
Enthesitis is typically defined as inflammation of the insertion of tendons, ligaments, aponeurosis, and capsules into the bone, and it is considered a pathological, clinical, and imaging hallmark of the spondyloarthritis (SpA) group, including psoriatic arthritis (PsA) [1,2,3]
Since 1994, US has been used for evaluating peripheral enthesitis in SpA patients in both lower and upper limb entheses [6,7,8,9]
Different clinical enthesitis scores [13,14,15] and US enthesitis scores [5, 16, 17] exist in literature, but currently there is no consensus on which clinical scores and US scores to apply
Summary
Enthesitis is typically defined as inflammation of the insertion of tendons, ligaments, aponeurosis, and capsules into the bone, and it is considered a pathological, clinical, and imaging hallmark of the spondyloarthritis (SpA) group, including psoriatic arthritis (PsA) [1,2,3]. The Assessments in the SpondyloArthritis International Working Group (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) have recommended enthesitis as one of the key domains for assessing disease activity and response in SpA (axial and peripheral) and PsA [4, 5]. The Outcome Measures in Rheumatology (OMERACT) Ultrasound (US) Working Group (WG), has developed and validated consensus-based US definitions for enthesitis lesions in SpA including PsA [1, 2] of which some are related to inflammation and some to inactive structural lesions. Little is known about the presence and response to treatment of US-detected enthesitis (inflammatory lesions and/or structural lesions) in axial SpA patients initiating TNF-I therapy due to axial inflammatory activity
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
